Quick answer: Cerebrolysin and Semax are both studied for neuroprotection and cognition, but they’re very different compounds. Cerebrolysin is a complex purified mixture of low-molecular-weight neuropeptides and amino acids from porcine brain, studied as a multi-target neurotrophic agent. Semax is a single defined synthetic peptide — an ACTH(4–10) analog — studied mainly for BDNF/TrkB-driven cognition and neuroplasticity. Sold for research use only.
The core distinction
The simplest framing: Cerebrolysin is a multi-component neurotrophic mixture; Semax is one well-defined molecule. Cerebrolysin hits many pathways at once (its defining feature), while Semax offers a single, standardized, more predictable mechanism centered on BDNF.
Side-by-side
| Cerebrolysin | Semax | |
|---|---|---|
| What it is | Purified mixture of low-MW neuropeptides + free amino acids (porcine brain-derived) | Synthetic heptapeptide, an ACTH(4–10) analog (no hormonal/cortisol effect) |
| Composition | Complex, multi-component | Single defined molecule |
| Primary studied mechanism | Multi-target: BDNF/NGF upregulation, anti-apoptotic and neurorestorative signaling | BDNF/TrkB upregulation; dopaminergic + serotonergic modulation |
| Main research angle | Broad neuroprotection / neurorecovery | Cognition, focus, neuroplasticity |
| Standardization | Mixture — harder to standardize | Defined peptide — predictable PK, easy to standardize |
Mechanisms in more detail
Cerebrolysin is not a single peptide but a standardized enzymatic breakdown of porcine brain proteins into low-molecular-weight neuropeptides and free amino acids. Its multi-target action is the defining pharmacological feature: it modulates several neuroprotective and neurorestorative pathways at once, including BDNF and NGF upregulation and anti-apoptotic signaling, rather than hitting a single receptor.
Semax is a defined synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of ACTH but stripped of hormonal/cortisol activity. Its cognitive mechanism centers on BDNF: a single application has been shown to raise hippocampal BDNF protein and TrkB phosphorylation, with several-fold increases in BDNF and TrkB mRNA, alongside dopaminergic and serotonergic modulation tied to attention and mood.
Why researchers study them together
Their mechanisms partially overlap (both upregulate BDNF/NGF and support neuroprotection) but differ in form: Cerebrolysin’s broad mixture versus Semax’s single-target precision. Researchers compare them to weigh multi-pathway coverage against standardization and predictable pharmacokinetics. PTW offers both individually.
Frequently asked questions
What is the difference between Cerebrolysin and Semax?
Cerebrolysin is a complex porcine-derived neuropeptide mixture acting on multiple neurotrophic pathways; Semax is a single defined ACTH(4–10) analog studied mainly for BDNF/TrkB-driven cognition.
Is Cerebrolysin a peptide?
Not a single one — it’s a purified mixture of many low-molecular-weight neuropeptides and free amino acids, which is why its mechanism is multi-target.
Is Semax derived from a hormone?
It’s an analog of the ACTH(4–10) fragment but retains neurotrophic activity without ACTH’s hormonal effects on cortisol or the adrenal axis.
Which is easier to standardize in research?
Semax. As a defined synthetic molecule it has more predictable pharmacokinetics; Cerebrolysin, being a mixture, is harder to standardize.
Are these for human use?
No. Portal to Wellness sells these strictly for laboratory and research use only. Nothing here is medical advice.
Primary-literature anchors
Cite primary sources: Dolotov et al. (Semax regulates BDNF and TrkB expression in rat hippocampus, Brain Research, 2006); Cerebrolysin neurotrophic/neurorestorative mechanism reviews (multi-target BDNF/NGF and anti-apoptotic signaling literature). Link via PubMed.
Related research & products
For research use only. Not for human or veterinary use, diagnosis, treatment, or prevention of any condition. Not evaluated by the FDA. Author: Charles Fowler. Last updated: May 2026.